Skip to main content

Table 5 Resistance proportion of priority bacteria-antimicrobial combinations in all specimens and in blood and CSF, in 2012 and 2016. Denominators and numerators are the numbers of tested and resistant isolates respectively. Corresponding resistant percentages are in brackets

From: Antimicrobial susceptibility testing results from 13 hospitals in Viet Nam: VINARES 2016–2017

  Bacteria All specimens Blood and CSF (stool for Salmonella spp. and Shigella spp.)
2012 (16 hospitals) 2012 (13 hospitals) 2016 2012 (16 hospitals) 2012 (13 hospitals) 2016
ESBL E. coli 1337/1928 (69%) 626/844 (74%) 4085/6953 (59%) 126/183 (69%) 59/81 (73%) 655/1107 (59%)
Imipenem E. coli 180/2 977 (6%) 145/2111 (7%) 687/8438 (8%) 15/403 (4%) 9/309 (3%) 92/1410 (7%)
Ceftriaxone E. coli 2342/4 192 (56%) 776/1472 (53%) 5051/7049 (72%) 240/514 (47%) 114/234 (49%) 912/1324 (69%)
MDR E. coli 453/1828 (25%) 441/1639 (27%) 2015/6956 (29%) 24/125 (19%) 24/125 (19%) 336/1204 (28%)
XDR E. coli 71/1828 (4%) 63/1639 (4%) 514/6956 (7%) 2/125 (2%) 2/125 (2%) 65/1204 (5%)
ESBL K. pneumoniae 887/1400 (63%) 555/815 (68%) 1186/2958 (40%) 91/172 (53%) 34/61 (56%) 128/365 (35%)
Imipenem K. pneumoniae 393/2 294 (17%) 259/1697 (15%) 891/3647 (24%) 64/361 (18%) 26/233 (11%) 91/454 (20%)
Ceftriaxone K. pneumoniae 1479/2 227 (66%) 626/1380 (45%) 1912/3436 (56%) 101/190 (53%) 63/175 (36%) 214/435 (49%)
MDR K. pneumoniae 318/1553 (20%) 294/1315 (22%) 428/3141 (14%) 17/112 (15%) 17/112 (15%) 53/403 (13%)
XDR K. pneumoniae 205/1553 (13%) 171/1315 (13%) 722/3141 (23%) 12/112 (11%) 12/112 (11%) 81/403 (20%)
Imipenem A. baumannii 1495/2138 (70%) 1056/1584 (67%) 2769/3551 (78%) 110/244 (45%) 85/205 (41%) 100/178 (56%)
MDR A. baumannii 897/1334 (67%) 897/1282 (70%) 2781/3442 (81%) 27/44 (61%) 27/44 (61%) 101/171 (59%)
Imipenem P. aeruginosa 578/1 765 (33%) 322/996 (32%) 1403/3220 (44%) 36/129 (28%) 22/88 (25%) 49/135 (36%)
MDR P. aeruginosa 178/576 (31%) 144/392 (37%) 660/1566 (42%) 4/25 (16%) 4/17 (24%) 17/70 (24%)
MRSA S. aureus 1 098/1 580 (69%) 950/1303 (73%) 3302/4515 (73%) 145/197 (74%) 130/171 (76%) 476/674 (71%)
Vancomycin* S. aureus 28/823 (3.4%) 10/372 (2%) 45/2680 (2%) 5/135 (3.7%) 0/65 (0%) 7/565 (1%)
Penicillin S. pneumoniae 115/344 (33%)** 115/341 (34%)** 663/1136(58%) 7/30 (23%) ** 7/30 (23%) ** 42/114 (37%)
Ceftriaxone S. pneumoniae 90/358 (25%) 31/299 (10.4%) 57/352 (16%) 9/52 (17%) 4/47 (8.5%) 17/125 (14%)
Vancomycin E. faecium 20/79 (25%) 20/79 (25%) 91/290 (31%) 2/14 (14%) 2/14 (14%) 13/51 (25%)
Ampicillin H. influenzae 160/226 (71%) 1/1 (100%) 804/911 (88%) 3/5 (60%) 1/1 (100%) 7/8 (88%)
  1. ESBL: extended-spectrum β-lactamase; *: Intermediate and Resistant; **: Combination result of oxacillin screening and penicillin MIC test; MDR: Multi-drug resistant; XDR: Extensively drug resistant; MRSA: Methicillin-resistant Staphylococcus aureus